Cost-effectiveness of Total Neoadjuvant Therapy With Short-Course Radiotherapy for Resectable Locally Advanced Rectal Cancer
Authors:
Open Access
- 1 February 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (2) , e2146312
Abstract
Colorectal cancer is the second leading cause of cancer-related mortality in the US, with the country’s second-highest annual cost of $14.1 billion in 2010.1 Costs were projected to reach $17.4 billion in 2020.1 Standard of care in the management of locally advanced rectal cancer usually entails neoadjuvant long-course chemoradiotherapy (LCCRT) for 5 to 6 weeks,2,3 followed by total mesorectal excision (TME).4,5 Although this treatment strategy has led to decreased local recurrence rates of 4% to 9%,5-7 distant metastases remain the predominant site of recurrence,8 and the management of metastatic rectal cancer incurs significant cost and morbidity.9Keywords
This publication has 54 references indexed in Scilit:
- Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04Journal of Clinical Oncology, 2012
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011
- Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03Journal of Clinical Oncology, 2009
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trialThe Lancet, 2009
- Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal CancerJournal of Clinical Oncology, 2006
- Swedish Rectal Cancer Trial: Long Lasting Benefits From Radiotherapy on Survival and Local Recurrence RateJournal of Clinical Oncology, 2005
- The Modern Abdominoperineal ExcisionAnnals of Surgery, 2005
- Cost-Utility Analysis of Preoperative Radiotherapy in Patients With Rectal Cancer Undergoing Total Mesorectal Excision: A Study of the Dutch Colorectal Cancer GroupJournal of Clinical Oncology, 2004
- Analysis of Surgical Salvage After Failure of Primary Therapy in Rectal Cancer: Results From Intergroup Study 0114Journal of Clinical Oncology, 2003
- The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?British Journal of Surgery, 1982